Navigation Links
ADVENTRX Reports Third Quarter 2012 Financial Results
Date:11/5/2012

SAN DIEGO, Nov. 5, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today reported financial results for the quarter ended September 30, 2012.

"With a strong cash position of approximately $40 million, we are well positioned to start our phase 3 study of ANX-188 in sickle cell disease," stated Brian M. Culley, Chief Executive Officer of ADVENTRX.  "We are pleased that we have finalized the protocol and completed the majority of our manufacturing activities that will enable us to start the study by the end of 2012," Mr. Culley continued. 

Third Quarter 2012 Operating ResultsADVENTRX's net loss for the third quarter of 2012 was $3.2 million, or $0.07 per share (basic and diluted), compared to a net loss of $3.5 million, or $0.13 per share (basic and diluted), for the same period in 2011.

Research and development (R&D) expenses for the third quarter of 2012 were $1.7 million, a decrease of $0.4 million, or 19%, compared to $2.1 million for the same period in 2011. The net decrease was primarily due to a $0.8 million decrease in external nonclinical study fees and expenses, which was offset by increases of $0.3 million in personnel costs and $0.1 million in external clinical study fees and expenses. The decrease in external nonclinical study fees and expenses resulted primarily from decreases in research-related manufacturing expenses of $1.1 million for ExelbineTM and $0.2 million for ANX-514.  The increase in personnel costs was primarily related to increased headcount, including relocation and recruitment costs for our new Chief Medical Officer.

Selling, general and administrative (SG&A) expenses for the third quarter of 2012 were $1.8 million, a decrease of $0.2 million, or 8%, compared to $2.0 million for the same period in 2011. The decrease resulted primarily from a decrease in consulting fees and legal expenses due to cost-savings realized by discontinuation of commercial-rea
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
2. ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors
3. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
4. ADVENTRX Announces Appointment Of Chief Medical Officer
5. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
6. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
7. ADVENTRX Pharmaceuticals To Present At The OneMedForum New York 2012 Emerging Company Finance Conference On July 12
8. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
9. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
10. Endo Reports Third Quarter Financial Results And Updates 2012 Financial Guidance
11. InspireMD Reports Results For Period Ending Sept. 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... According to the new ... therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, ... Global Forecast to 2019" published by MarketsandMarkets, the global ... Million by 2019 from $14,240.0 Million in 2014, ... 2019. Browse 74 market data tables ...
(Date:9/19/2014)... WASHINGTON , Sept. 19, 2014 The ... that Drive Medical Design and Manufacturing has joined the ... its CEO Harvey Diamond have been actively ... year history, as it has quickly grown into a ... corporate partners like Drive allows AAHomecare to increase efforts ...
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
Breaking Medicine Technology:Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3
... 2011 BioMed Realty Trust, Inc. (NYSE: ... of its 2010 distributions as follows:Security Description: Common ... ShareAllocable to 2010Taxable Ordinary DividendReturn of CapitalLong-Term Capital ... , $0.140000 , $0.090527 , $0.049473 , $0.000000 ...
... Jan. 19, 2011 Pervasis Therapeutics, Inc. today announced ... therapy (PVS-30200) to target and regulate cell stroma (the ... supporting cell types distinct from cancer cells) in order ... advancing solid tumor growth and metastasis (the spread of ...
Cached Medicine Technology:BioMed Realty Trust Announces Tax Treatment of 2010 Distributions 2Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence 2Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence 3Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence 4Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence 5
(Date:9/20/2014)... Lifeinsurancequoteterm.net has released a new blog post ... insurance plan provides for vulnerable family members. , ... a top priority for every provider. It is now ... examinations and visiting a doctor. , Life insurance ... coverage up to $300,000, but only to healthy applicants. ...
(Date:9/20/2014)... New PharmaPoint Drug Evaluation report, “Symbicort ... The asthma market saw very slow growth over ... with relatively efficacious standard therapies, such as short-acting ... long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has ... launch of seven novel targeted biologic agents and ...
(Date:9/20/2014)... have advised their patients against drinking coffee and wine. Dr. ... advice and changing his stance after considering two recent studies ... health. “There’s good news and great news,” says Dr. Wells, ... against gum disease, and red wine can help fight cavities!” ... September 2014 issue of Boston University School of Medicine ...
(Date:9/20/2014)... QueenBeeTickets.com is ready to offer discount Ariana ... will visit many cities in North America next year ... April. , Click Here to view the ... , The star’s fans are not going to want ... singer in a live performance. Ariana Grande concert tickets ...
(Date:9/20/2014)... “Motherhood is a wonderful gift and a huge ... latest article , “We know that you want to care ... we want to do as well.” , The article explains ... from their Family Physicians who practice obstetrics while pregnant, during ... , To learn more about Community Health Center of Snohomish ...
Breaking Medicine News(10 mins):Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2
... Beginning, March 17, 2009, the first of two effective ... Final Rule goes into effect. This final rule ... Version 4010A1 and National Council for Prescription Drug Programs ... transactions. Compliance with these standards is mandatory by ...
... Quantum Group, Inc. (NYSE Amex: QGP ) ( ... received notice on March 17, 2009 from the NYSE Amex ... it is not in compliance with Section 1003(a)(iv) of the ... sustained losses which are so substantial in relation to its ...
... may be driving the trend, doctors say , , FRIDAY, March ... reporting a sharp increase in the number of vasectomies performed ... many of his clients are from the beleaguered financial industry. ... both to a decreased desire to have children because of ...
... rigorous environmental cleaning intervention can reduce the transmission of ... organisms in hospital intensive care units (ICUs), according to ... of the Society for Healthcare Epidemiology of America (SHEA). ... reduced the spread of MRSA to patients exposed to ...
... for decades as a significant problem affecting astronauts. ... gravity is causing astronauts on the International Space Station ... in key regions of the body each month than ... time back here on Earth., Now, by simulating spaceflight ...
... implications for public safety, experts say , , FRIDAY, ... percent of candidates for fire and ambulance services ... situation that has major consequences for public health ... and musculoskeletal injury are important causes of [disability ...
Cached Medicine News:Health News:Edifecs Announces New Version of Its Integrated HIPAA 5010 and ICD-10 Analysis and Migration Solution 2Health News:Edifecs Announces New Version of Its Integrated HIPAA 5010 and ICD-10 Analysis and Migration Solution 3Health News:The Quantum Group Receives a NYSE Amex Notification of a Listing Deficiency 2Health News:The Quantum Group Receives a NYSE Amex Notification of a Listing Deficiency 3Health News:The Quantum Group Receives a NYSE Amex Notification of a Listing Deficiency 4Health News:The Quantum Group Receives a NYSE Amex Notification of a Listing Deficiency 5Health News:With the Economy Down, Vasectomy Rates Are Up 2Health News:Environmental Cleaning Intervention Reduces Transmission of Multidrug-Resistant Organisms in ICUs 2Health News:University of Washington scientists one step closer to stopping bone loss during spaceflight 2Health News:Most New EMS Recruits Overweight or Obese 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: